Brookfield Corp’s Generation Bio GBIO Stock Holding History

Brookfield Corp’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,000	Closed	-$420K	–	410
2020 Q2	$420K	Buy	+2,000	New	+$446K	﹤0.01%	320

Other funds holding GBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Brookfield Corp's GBIO Position: Q3 2020 in Review

Brookfield Corp sold out of Generation Bio (GBIO) in Q3 2020, closing a stake of 2,000 shares — an estimated $420K sold.

Brookfield Corp first reported a position in GBIO in Q2 2020 and held it in 1 quarter. The position peaked at $420K in Q2 2020. 53 funds tracked by Wall St. Rank hold GBIO as of Q3 2020.

Brookfield Corp reported no remaining Generation Bio position as of Q3 2020 after selling out during the quarter.
Brookfield Corp sold 2,000 Generation Bio shares in Q3 2020, an estimated $420K.
Brookfield Corp first reported a position in Generation Bio in Q2 2020 and held it in 1 quarter.
Brookfield Corp's Generation Bio position peaked at $420K in Q2 2020.
53 funds tracked by Wall St. Rank held Generation Bio as of Q3 2020.

Based on Brookfield Corp's 13F filing for Q3 2020, filed 16 Nov 2020.